• Amazon.com (NasdaqGS:AMZN) is partnering with Eli Lilly to offer the newly approved oral GLP-1 weight loss drug Foundayo through Amazon Pharmacy.
• Patients in thousands of U.S. cities can access Foundayo via same day delivery or in office pickup, including through One Medical locations.
• This move reflects a broader push by Amazon into obesity care and prescription delivery across its healthcare services.

For investors watching Amazon beyond e commerce and cloud, this step deepens the company’s involvement in healthcare services and pharmacy. Obesity drugs have become a key area of focus across healthcare and consumer sectors, and Amazon is positioning its pharmacy offering directly in that space with Eli Lilly’s oral GLP-1 treatment.

The combination of Amazon Pharmacy, same day logistics and One Medical in office access gives Amazon another way to integrate healthcare into its broader ecosystem. For shareholders tracking NasdaqGS:AMZN, this development highlights one more element of how the company may seek to use its scale, logistics network and clinical footprint to support healthcare initiatives.

Stay updated on the most important news stories for Amazon.com by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amazon.com.

📰 Beyond the headline: 1 risk and 3 things going right for Amazon.com that every investor should see.

For Amazon, carrying Eli Lilly’s Foundayo through Amazon Pharmacy puts the company closer to a fast-growing segment of healthcare: obesity treatment delivered via prescriptions. The pill’s oral format and lack of refrigeration requirements make it suitable for Amazon’s same-day delivery model, so this is less about new drug economics and more about using logistics, Prime, and One Medical to own more of the patient journey. By offering real-time availability, price transparency, and coupon integration, Amazon increases reasons for existing customers to keep prescriptions within its ecosystem instead of at traditional chains like CVS, Walgreens, or Walmart. For investors, the key angle is how healthcare touches can feed into higher engagement across retail, Prime membership, and potentially advertising, while also layering another use case on top of Amazon’s fulfillment network. At the same time, distributing GLP-1 weight-loss drugs increases Amazon’s exposure to regulatory, reimbursement, and supply questions that have surrounded this drug class, so execution and compliance will be central to how attractive this line of business becomes over time.

How This Fits Into The Amazon.com Narrative

• The Foundayo launch supports the existing narrative that Amazon is broadening recurring, service-based revenue streams, because pharmacy and obesity care can deepen Prime stickiness alongside AWS, advertising, and retail.
• The move into prescription weight-loss treatment also challenges the idea that margin expansion will only be driven by cloud and logistics efficiency, since healthcare services bring their own regulatory and operational costs that could influence profitability.
• The current narrative focuses heavily on cloud, AI, and logistics, while the specific risks of GLP-1 obesity drugs, such as reimbursement changes or supply constraints, are not fully captured and may need to be factored into future storylines.

Knowing what a company is worth starts with understanding its story.
Check out one of the top narratives in the Simply Wall St Community for Amazon.com to help decide what it’s worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Greater involvement in obesity care exposes Amazon to healthcare-specific risks, including regulatory scrutiny, changing insurance coverage, and any safety or supply issues tied to GLP-1 drugs like Foundayo.
• ⚠️ Scaling same-day delivery for high-demand medications increases operational complexity, so any service failures or data issues in Amazon Pharmacy could affect customer trust across the wider brand.
• 🎁 Adding Foundayo to Amazon Pharmacy and One Medical gives Amazon a higher-value use case for its logistics and clinic network, which can support higher engagement and potentially better utilization of existing infrastructure.
• 🎁 If Amazon can make access to obesity treatment simpler and more predictable on price, it may win share from traditional pharmacies and strengthen the broader Prime and healthcare ecosystem against competitors such as CVS, Walgreens, and Walmart Health.

What To Watch Going Forward

From here, focus on how quickly Amazon expands Foundayo coverage beyond the initial 3,000 cities and how often management references pharmacy or obesity care when talking about customer engagement. It is also worth watching how regulators and insurers treat GLP-1 weight-loss drugs, because changes in coverage, pricing, or prescribing could influence prescription volumes flowing through Amazon Pharmacy. Finally, keep an eye on whether Amazon adds more chronic-care offerings or bundled health services, which would signal that obesity treatment is part of a broader push rather than a one-off product launch.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Amazon.com, head to the
community page for Amazon.com to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com